Business
Voyageur Pharmaceuticals Ltd. Announces Issuance of Stock Options
(TheNewswire) Calgary, Alberta – TheNewswire - Apr...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Pharmaceuticals Ltd. Announces Issuance of Stock Options\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Calgary, Alberta –\n \n \n TheNewswire\n-\n \n \n April 5\n \n \n th\n \n \n , 2021 –\nVoyageur Pharmaceuticals Ltd. (\n \n \n TSX.V:VM)\n \n \n (\n \n \n OTC:VYYRF\n \n \n ) (the\n\"Company\" or \"Voyageur\")  announced that is has\nissued 2,625,000 options to directors, officers and consultants\npursuant to its incentive stock option plan (the \"Options\").\n On March 29, 2021, the Company's board of directors approved the\ngrant of Options, to be effective on April 1, 2021 using the closing\nprice on that day.  The Options were issued with an exercise price of\n$0.175 per common share, vest immediately, and have a\n \n \n 10 year term.  The Options are subject to regulatory and TSX\nVenture Exchange approval.\n \n \n \n \n About Voyageur\n \n \n \n \n Voyageur Pharmaceuticals Ltd. is Canadian public\ncompany listed on the TSX Venture Exchange under the trading symbol\nVM. Voyageur is focused on the development of barite and iodine,\nActive Pharmaceutical Ingredient (API) minerals. The near-term focus\nis developing barium and iodine radio-contrast pharmaceutical\nproducts. Voyageur’s goal is to initially generate near term\npositive cash flow from operations using third party GMP\npharmaceutical manufacturers in Canada and internationally.\nUltimately, Voyageur has plans to build all the required\ninfrastructure to become 100% self-sufficient with all manufacturing.\nVoyageur owns a 100% interest in three barium sulfate (barite)\nprojects including two properties suitable in grade for the industrial\nbarite marketplace, with interests in a potentially high-grade iodine,\nlithium & bromine brine project located in Utah, USA.\n \n \n \n \n Voyageur is moving forward with its business plan of\nbecoming the only fully-integrated company in the radiographic\ncontrast medical field, by controlling all primary input costs under\nthe motto of:\n \n \n \"From the\nEarth to the Bottle\"\n \n \n \n \n For Further Media Information or to set up an\ninterview, please contact:\n \n \n \n \n Brent Willis\n \n \n \n \n President & CEO\n \n \n \n \n E\n \n \n \n \n [email protected]\n \n \n \n \n \n \n Ron Love\n \n \n \n \n CFO\n \n \n \n \n T 403.818.6086...